Renal insufficiency in non-diabetic subjects: Relationship of MTHFR C677t gene polymorphism and left ventricular hypertrophy

Renal Failure

Volumn 35, Issue 5, 2013, Pages 615-623

  Trovato, Guglielmo M ^a   Catalano, Daniela ^a   Ragusa, Angela ^b   Martines, G Fabio ^c   Tonzuso, Antonia ^a   Pirri, Clara ^a   Buccheri, Maria Antonietta ^b   Di Nora, Concetta ^a   Trovato, Francesca M ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Prenatal Diagnosis and Medical Genetics AOU VE and Policlinico   (Italy)

^c Chugai USA Inc   (United States)

Author keywords

Echocardiography; Genetic; GFR; Homocysteine; Insulin resistance; Left ventricular hypertrophy; Mediterranean diet; MTHFR polymorphism; Obesity; Renal function

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); C REACTIVE PROTEIN; HOMOCYSTEINE; INSULIN; PARATHYROID HORMONE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BODY MASS; DNA POLYMORPHISM; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERPARATHYROIDISM; INSULIN RESISTANCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESISTIVE INDEX;

ADULT; AGED; C-REACTIVE PROTEIN; DIET; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; LINEAR MODELS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PARATHYROID HORMONE; POLYMORPHISM, SINGLE NUCLEOTIDE; RENAL INSUFFICIENCY;

EID: 84877864851     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.779895     Document Type: Article

References (78)

1. Fung MM, Salem RM, Lipkowitz MS, et al. Methylene tetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC). Nephrol Dial Transplant. 2012;27:197-205
2. Morita H, Taguchi J, Kurihara H, et al. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 1997;128:107-112
3. Minamino T, Ohno M, Yamaoki K, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997; 95:2032-2036 (Pubitemid 27184270)
4. van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 1997;95:21-23 (Pubitemid 27029937)
5. Deloughery TG, Evans A, Sadeghi A, et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation. 1996;94:3074-3078 (Pubitemid 26427468)
6. Kang SS, Passen EL, Ruggie N, Wong PW, Sora H. Thermo labile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993;88(4 Pt 1):1463-1469 (Pubitemid 23296892)
7. Gülec S, Aras O, Akar E, Tutar E, et al. Methylene-Tetrahydrofolate reductase gene polymorphism and risk of premature myocardial infarction. Clin Cardiol. 2001;24:281-284 (Pubitemid 32285308)
8. Brattström L, Zhang Y, Hurtig M, et al. A common methylenetetrahydrofolate reductase gene mutation and longevity. Atherosclerosis. 1998;141:315-319 (Pubitemid 28539639)
9. Agodi A, Barchitta M, Cipresso R, et al. Distribution of p53, GST, and MTHFR polymorphisms and risk of cervical intraepithelial lesions in Sicily. Int J Gynecol Cancer. 2010;20:141-146
10. Chen J, Giovannucci E, Kelsey K, et al. A methylenetetrahydrofolate reductase polymorphism and the risk of colorectal cancer. Cancer Res. 1996;56:4862-4864 (Pubitemid 26374419)
11. Martínez ME, Thompson P, Jacobs ET, et al. Dietary factors and biomarkers involved in the methylenetetrahydrofolate reductase genotype-colorectal adenoma pathway. Gastroenterology. 2006;131:1706-1716 (Pubitemid 44958511)
12. Lee JE, Wei EK, Fuchs CS, et al. Plasma folate, methylenetetrahydrofolate reductase (MTHFR), and colorectal cancer risk in three large nested case-control studies. Cancer Causes Control. 2012;23:537-545
13. Rea IM, McMaster D, Woodside JV, et al. Community-living nonagenarians in Northern Ireland have lower plasma homocysteine but similar methylenetetrahydrofolate reductase thermolabile genotype prevalence compared to 70-89-year-old subjects. Atherosclerosis. 2000;149:207-214 (Pubitemid 30125990)
14. Ravera M, Viazzi F, Berruti V, et al. 5,10-Methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. Am J Hypertens. 2001;14(4 Pt 1):371-376
15. Dedoussis GV, Panagiotakos DB, Pitsavos C, et al. ATTICA Study Group. An association between the methylenetetrahydrofolate reductase (MTHFR) C677T mutation and inflammation markers related to cardiovascular disease. Int J Cardiol. 2005;100:409-414
16. Trovato GM, Pirri C, Martines GF, Trovato F, Catalano D. Coffee, nutritional status, and renal artery resistive index. Ren Fail. 2010;32:1137-1147
17. Greaves K, Chen R, Ge L, et al. Mild to moderate renal impairment is associated with increased left ventricular mass. Int J Cardiol. 2008;124:384-386 (Pubitemid 351305367)
18. Hsieh MC, Su HM, Wang SY, et al. Significant correlation between left ventricular systolic and diastolic dysfunction and decreased glomerular filtration rate. Ren Fail. 2011;33:977-982
19. Rodrigues SL, Angelo LC, Pereira AC, Krieger JE, Mill JG. Determinants of left ventricular mass and presence of metabolic risk factors in normotensive individuals. Int J Cardiol. 2009;135:323-330
20. Lai CL, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT. Left ventricular mass and risk of cardiovascular events and all-cause death among ethnic Chinese-The Chin-Shan Community Cardiovascular Cohort study. Int J Cardiol. 2011;149:347-352
21. Rivera Otero JM, Taléns-Visconti R, Salvador A, et al. Grupo de Disfunción VI, Comunidad Valenciana. Ventricular hypertrophy increases NT-proBNP in subjects with and without hypertension. Int J Cardiol. 2004;96:265-271 (Pubitemid 38979909)
22. de Ruijter W, Westendorp RG, Assendelft WJ, et al. Use of Framingham risk score and new biomarkers to predict cardiovascular mortality in older people: Population based observational cohort study. BMJ. 2009;338:a3083-A3090
23. Wald DS, Law M, Morris JK. The dose-response relation between serum homocysteine and cardiovascular disease: Implications for treatment and screening. Eur J Cardiovasc Prev Rehabil. 2004;11:250-253 (Pubitemid 38870075)
24. Brattström L, Wilcken DE. Homocysteine and cardiovascular disease: Cause or effect? Am J Clin Nutr. 2000;72:315-323 (Pubitemid 30620632)
25. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr. 2000;72:324-332 (Pubitemid 30623491)
26. Kopple JD. The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr. 2005;81:1257-1266 (Pubitemid 41710225)
27. Dedoussis GV, Panagiotakos DB, Chrysohoou C, et al. Effect of interaction between adherence to a Mediterranean Diet and the methylenetetrahydrofolate reductase 677C->T mutation on homocysteine concentrations in healthy adults: The ATTICA Study. Am J Clin Nutr. 2004;80:849-854 (Pubitemid 41202081)
28. Doehner W, Clark A, Anker SD. The obesity paradox: Weighing the benefit. Eur Heart J. 2010;31:146-148
29. Tublin ME, Bude RO, Platt JF. Review. The resistive index in renal Doppler sonography: Where do we stand? AJR Am J Roentgenol. 2003;180:885-892 (Pubitemid 36363021)
30. Heine GH, Reichart B, Ulrich C, Köhler H, Girndt M. Do ultrasound renal resistance indices reflect systemic rather than renal vascular damage in chronic kidney disease? Nephrol Dial Transplant. 2007;22:163-170 (Pubitemid 46050341)
31. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J. 2003;24:2054-2060 (Pubitemid 37420453)
32. Anderson JL, Vanwoerkom RC, Horne BD, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: Dependent or independent risk factors? Am Heart J. 2011;162:331-339
33. Trovato GM, Martines GF, Trovato FM, Pirri C, Pace P, Catalano D. Renal resistive index and parathyroid hormone relationship with renal function in nondiabetic patients. Endocr Res. 2012;37:47-58
34. Bell DS. Insulin resistance. An often unrecognized problem accompanying chronic medical disorders. Postgrad Med. 1993;93(99-103):106-107
35. Pitsavos C, Panagiotakos DB, Chrysohoou C, Stefanadis C. Epidemiology of cardiovascular risk factors in Greece: Aims, design and baseline characteristics of the ATTICA study. BMC Publ Health. 2003;3:32-40
36. Catalano D, Trovato GM,Martines GF, RandazzoM, Tonzuso A. Bright liver, body composition and insulin resistance changes with nutritional intervention: A follow-up study. Liver Int. 2008;28:1280-1287
37. Dai J, Jones DP, Goldberg J, et al. Association between adherence to the Mediterranean Diet and oxidative stress. Am J Clin Nutr. 2008;88:1364-1370
38. Trichopoulou A, Kouris-Blazos A, Wahlqvist ML, et al. Diet and overall survival in elderly people. BMJ. 1995;31:1457-1460
39. Trichopoulou A, Vasilopoulou E. Mediterranean Diet and longevity. Br J Nutr. 2000;84(Suppl 2):S205-S209 (Pubitemid 32140601)
40. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean Diet and survival in a Greek population. N Engl J Med. 2003;348:2599-2608 (Pubitemid 36741587)
41. Bravata DM, Smith-Spangler C, Sundaram V, et al. Using pedometers to increase physical activity and improve health: A systematic review. J Am Med Assoc. 2007;298:2296-2304 (Pubitemid 350146220)
42. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(Suppl 3):S1-S201
43. La'ulu SL, Rawlins ML, Pfeiffer CM, Zhang M, Roberts WL. Performance characteristics of six homocysteine assays. Am J Clin Pathol. 2008;130:969-975
44. Rutter MK, Wilson PW, Sullivan LM, Fox CS, D'Agostino RBSr, Meigs JB. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. Circulation. 2008;117:1003-1009
45. Trovato GM, Catalano D, Sciacchitano G, Zuccalà G, Iannetti E. Resistive index of renal artery and blood pressure in postmenopausal women. Maturitas. 2002;41:223-230 (Pubitemid 34211977)
46. Trovato GM, Pirri C, Martines GF, Tonzuso A, Trovato F, Catalano D. Lifestyle interventions, insulin resistance, and renal artery stiffness in essential hypertension. Clin Exp Hypertens. 2010;32:262-269
47. Gardin JM, Adams DB, Douglas PS, et al. American Society of Echocardiography. Recommendations for a standardized report for adult transthoracic echocardiography: A report from the American Society of chocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr. 2002; 15:275-290 (Pubitemid 44970067)
48. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083 (Pubitemid 9091990)
49. Woythaler JN, Singer SL, Kwan OL, et al. Accuracy of echocardiography versus electrocardiography in detecting left ventricular hypertrophy: Comparison with postmortem mass measurements. J Am Coll Cardiol. 1983;2:305-311 (Pubitemid 13078796)
50. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol. 1986;57:450-458 (Pubitemid 16119719)
51. Guéant-Rodriguez RM, Guéant JL, Debard R, et al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: A comparative study in Mexican, West African, and European populations. Am J Clin Nutr. 2006;83:701-707 (Pubitemid 44699219)
52. Foppa M, Duncan BB, Rohde LE. Echocardiography-based left ventricular mass estimation. How should we define hypertrophy? Cardiovasc Ultrasound. 2005;3:17-30
53. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-Analysis. J Am Coll Cardiol. 2006;47:1987-1996
54. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y. C-reactive protein, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertens Res. 2007;30:1177-1185 (Pubitemid 351176415)
55. Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease; a review. Eur Heart J. 2004;25:1776-1787 (Pubitemid 39330228)
56. Fox ER, Benjamin EJ, Sarpong DF, et al. The relation of C-reactive protein to chronic kidney disease in African Americans: The Jackson Heart Study. BMC Nephrol. 2010;11:1-7
57. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: A review. Kidney Int. 2011;80:806-821
58. Petersen LJ, Petersen JR, Talleruphuus U, Ladefoged SD, Mehlsen J, Jensen HA. The pulsatility index and the resistive index in renal arteries. Associations with long-Term progression in chronic renal failure. Nephrol Dial Transplant. 1997;12: 1376-1380 (Pubitemid 27353026)
59. Catalano D, Trovato GM, Martines GF, Pirri C, Trovato FM. Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate. Hepatol Int. 2011;5:822-829
60. Maurer M, Burri S, de Marchi S, et al. Plasma homocysteine and cardiovascular risk in heart failure with and without cardiorenal syndrome. Int J Cardiol. 2010;141:32-38
61. Yi F, Li PL. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am J Nephrol. 2008;28:254-264
62. Rutter MK, Parise H, Benjamin EJ, et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: Sex-related differences in the Framingham Heart Study. Circulation. 2003;107:448-454 (Pubitemid 36158048)
63. Velagaleti RS, Gona P, Chuang ML, et al. Relations of insulin resistance and glycemic abnormalities to cardiovascular magnetic resonance measures of cardiac structure and function: The Framingham Heart Study. Circ Cardiovasc Imaging. 2010;3:257-263
64. Cheng HT, Huang JW, Chiang CK, Yen CJ, Hung KY,WuKD. Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. J Clin Endocrinol Metab. 2012;97:1268-1276
65. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial. J Am Coll Cardiol. 2006;47:1108-1116
66. Boner G. Renal involvement and left ventricular hypertrophy are novel risk factors for morbidity and mortality in diabetes mellitus. Diabetes Metab Res Rev. 2011;27:425-429
67. Florea VG, Mareyev VY, Samko AN, Orlova IA, Coats AJ, Belenkov YN. Left ventricular remodelling: Common process in patients with different primary myocardial disorders. Int J Cardiol. 1999;68:281-287 (Pubitemid 29138938)
68. Thomas MD, Fox KF, Coats AJ. Redefining heart failure. Int J Cardiol. 2006;112:139-141 (Pubitemid 44354970)
69. de Lorgeril M, Salen P.Mediterranean Diet in secondary prevention of CHD. Public Health Nutr. 2011;14:2333-2337
70. Coats AJ. Advances in the non-drug, non-surgical, non-device management of chronic heart failure. Int J Cardiol. 2005; 100:1-4 (Pubitemid 40487929)
71. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. Adherence to the Mediterranean Diet is associated with renal function among healthy adults: The ATTICA study. J Ren Nutr. 2010;20:176-184
72. Pereira AC, Miyakawa AA, Lopes NH, et al. Dynamic regulation of MTHFR mRNA expression and C677T genotype modulate mortality in coronary artery disease patients after revascularization. Thromb Res. 2007;121:25-32 (Pubitemid 350026000)
73. Kalina A, Czeizel AE. The methylenetetrahydrofolate reductase gene polymorphism (C677T) is associated with increased cardiovascular mortality in Hungary. Int J Cardiol. 2004;97:333-334 (Pubitemid 39286862)
74. Collings A, Raitakari OT, Juonala M, et al. Associations of methylenetetrahydrofolate reductase C677T polymorphism with markers of subclinical atherosclerosis: The cardiovascular risk in Young Finns Study. Scand J Clin Lab Invest. 2008;68:22-30 (Pubitemid 351161509)
75. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: A case-control study. Circulation. 1996;94:1812-1814 (Pubitemid 26349290)
76. Yang Q, Bailey L, Clarke R, et al. Prospective study of methylenetetrahydrofolate reductase (MTHFR) variant C677T and risk of all-cause and cardiovascular disease mortality among 6000US adults. Am J Clin Nutr. 2012;95:1245-1253
77. Schofield RS, Wessel TR, Walker TC, Cleeton TS, Hill JA, Aranda JM Jr. Hyper-homocysteinemia in patients with heart failure referred for cardiac transplantation: Preliminary observations. Clin Cardiol. 2003;26:407-410 (Pubitemid 37072052)
78. Bowden RG, Wyatt FB, Wilson R, Wilborn C, Gentile M. Homocysteine and vascular access thrombosis in a cohort of end-stage renal disease patients. Ren Fail. 2004;26:709-714 (Pubitemid 39579134)